Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975, with postgraduate training in psychiatry at St. Vincent’s Hospital and the Medical Center of New York Medical College. Currently, he is the Lawrence C. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. He also holds the Lieber Chair for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as Psychiatrist in Chief at New York-Presbyterian Hospital, Columbia University Medical Center.
Dr. Lieberman’s research has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs. He served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), sponsored by the NIMH. He also currently serves as Principal Investigator on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE). His extensive publications include over 450 journal articles, and he has edited 12 books, including the textbook Psychiatry (currently in its 3rd edition); Textbook of Schizophrenia; Comprehensive Care of Schizophrenia, Psychiatric Drugs, and Ethics in Psychiatric Research.
As Associate Editor, he has lent his expertise to several leading journals in the field, including Biological Psychiatry, American Journal of Psychiatry, Schizophrenia Bulletin, Neuropsycho-pharmacology, and Schizophrenia Research. Dr. Lieberman is a member of the National Academy of Sciences Institute of Medicine and a fellow of the American Association for the Advancement of Science (AAAS). He has received numerous awards, including the Lieber Prize for Schizophrenia Research from NARSAD, the APA’s Adolph Meyer Award (as well as the APA's Research, Kempf and Gralnick Awards), the American College of Psychiatry’s Stanley R. Dean Award for Schizophrenia Research, the Society of Biological Psychiatry’s Ziskind-Somerfeld Award, the Ernest Strecker Award of the University of Pennsylvania, the Exemplary Psychiatrist Award from the National Alliance of the Mentally Ill, and the Lilly Neuroscience Award from the Collegium Internationale Neuro-Psychopharmacologicum for Clinical Research. He is or has been a member of the FDA advisory committee for neuropharmacologic and psychopharmacologic drugs, the Planning Board for the Surgeon General’s Report on Mental Health, the APA Committee on Research on Psychiatric Treatments, the APA Work Group for the Development of Schizophrenia Treatment Guidelines, the Brain Disorders and Clinical Neuroscience Review Committee, and the NIMH National Advisory Mental Health Council. He is currently Vice President of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) and chairs the Council on Research and Quality Care for the American Psychiatric Association (APA).